Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roflumilast - AstraZeneca

Drug Profile

Roflumilast - AstraZeneca

Alternative Names: APTA-2217; B 9302-107; BY 217; BYK 20869; Daliresp; Daxas; IN-ALR 01; Libertek

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALTANA Pharma
  • Developer Actavis; Almirall S.A.; AstraZeneca; Mitsubishi Tanabe Pharma Corporation; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Aminopyridines; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Discontinued Alzheimer's disease; Asthma; Atopic dermatitis; Non-alcoholic steatohepatitis; Plaque psoriasis; Schizophrenia; Type 2 diabetes mellitus

Most Recent Events

  • 18 May 2018 Pharmacodynamics data from a phase III trial in Chronic obstructive pulmonary disease presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 05 Apr 2018 Discontinued - Phase-I for Alzheimer's disease (Combination therapy, In volunteers) in United Kingdom (PO)
  • 05 Apr 2018 Discontinued - Phase-I for Plaque psoriasis in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top